×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AGIO – agios pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AGIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
5/25
07:00 am
agio
Agios Appoints Catherine Owen to Board of Directors
Medium
Report
Agios Appoints Catherine Owen to Board of Directors
5/18
02:18 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/11
10:00 am
agio
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
Low
Report
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
5/5
11:24 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target lowered by analysts at SVB Securities from $37.00 to $34.00.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target lowered by analysts at SVB Securities from $37.00 to $34.00.
5/4
07:00 am
agio
Agios Reports Business Highlights and First Quarter 2023 Financial Results
High
Report
Agios Reports Business Highlights and First Quarter 2023 Financial Results
5/2
01:03 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
4/25
07:00 am
agio
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
Low
Report
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
4/21
01:02 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Date
Time
Symbol
Company Name
Action
%Chg
5/4/2023
07:00 am
agio
agios pharmaceuticals, inc.
BEAT
Report
11.0%
agios pharmaceuticals, inc.
11/3/2022
07:00 am
agio
agios pharmaceuticals, inc.
BEAT
Report
-5.2%
agios pharmaceuticals, inc.
8/4/2022
07:00 am
agio
agios pharmaceuticals, inc.
BEAT
Report
15.4%
agios pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
5/25
04:02 pm
agio
Form 8-K AGIOS PHARMACEUTICALS, For: May 22
Low
Report
Form 8-K AGIOS PHARMACEUTICALS, For: May 22
5/4
09:56 am
agio
Form 10-Q AGIOS PHARMACEUTICALS, For: Mar 31
Medium
Report
Form 10-Q AGIOS PHARMACEUTICALS, For: Mar 31
5/4
07:04 am
agio
Form 8-K AGIOS PHARMACEUTICALS, For: May 04
High
Report
Form 8-K AGIOS PHARMACEUTICALS, For: May 04
4/26
04:09 pm
agio
Form ARS AGIOS PHARMACEUTICALS, For: Dec 31
Low
Report
Form ARS AGIOS PHARMACEUTICALS, For: Dec 31
4/26
04:06 pm
agio
Form DEFA14A AGIOS PHARMACEUTICALS,
Low
Report
Form DEFA14A AGIOS PHARMACEUTICALS,
4/26
04:04 pm
agio
Form DEF 14A AGIOS PHARMACEUTICALS,
Low
Report
Form DEF 14A AGIOS PHARMACEUTICALS,
4/19
07:26 am
agio
Form 8-K AGIOS PHARMACEUTICALS, For: Apr 17
Low
Report
Form 8-K AGIOS PHARMACEUTICALS, For: Apr 17
4/12
04:18 pm
agio
Form 4 AGIOS PHARMACEUTICALS, For: Apr 08 Filed by: FOUSE JACQUALYN A
Medium
Report
Form 4 AGIOS PHARMACEUTICALS, For: Apr 08 Filed by: FOUSE JACQUALYN A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/13
Form 8-K AGIOS PHARMACEUTICALS, For: Jan 13
8.7%
11/5 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its price target lowered by analysts at Citigroup Inc from $80.00 to $64.00. They now have a "buy" rating on the stock. 7.9%
9/10 Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO 6.2%
10/2 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.6%
12/9 Form 8-K AGIOS PHARMACEUTICALS, For: Dec 08 5.4%
6/14 Form 4 AGIOS PHARMACEUTICALS For: Jun 12 Filed by: MARAGANORE JOHN 5.4%
2/13 Q4/2019 12/31/2019 EPS -1.600 ZacksConsensus -1.780 ActVsEst 0.180 - Beat 5.3%
7/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.1%
5/15 Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients 5.0%
4/16 Form DEF 14A AGIOS PHARMACEUTICALS, For: May 28 5.0%
11/5 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its price target lowered by analysts at Citigroup Inc from $80.00 to $64.00. They now have a "buy" rating on the stock. 7.9%
9/10 Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO 6.2%
10/2 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.6%
12/9 Form 8-K AGIOS PHARMACEUTICALS, For: Dec 08 5.4%
6/14 Form 4 AGIOS PHARMACEUTICALS For: Jun 12 Filed by: MARAGANORE JOHN 5.4%
2/13 Q4/2019 12/31/2019 EPS -1.600 ZacksConsensus -1.780 ActVsEst 0.180 - Beat 5.3%
7/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.1%
5/15 Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients 5.0%
4/16 Form DEF 14A AGIOS PHARMACEUTICALS, For: May 28 5.0%
TOP News Decliners
5/1
Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $72.00 price target on the stock.
-13.0%
8/1 Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30 -11.2%
12/9 Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) -8.8%
5/16 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.9%
4/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%
1/13 TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets -6.2%
10/28 Form 8-K AGIOS PHARMACEUTICALS, For: Oct 27 -6.2%
9/30 Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients -6.2%
2/24 Form 4 AGIOS PHARMACEUTICALS, For: Feb 20 Filed by: Alenson Carman -6.0%
2/14 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. -5.1%
8/1 Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30 -11.2%
12/9 Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) -8.8%
5/16 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.9%
4/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%
1/13 TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets -6.2%
10/28 Form 8-K AGIOS PHARMACEUTICALS, For: Oct 27 -6.2%
9/30 Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients -6.2%
2/24 Form 4 AGIOS PHARMACEUTICALS, For: Feb 20 Filed by: Alenson Carman -6.0%
2/14 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: